A federal judge denied a bid by CVS Health, Cigna and UnitedHealth Group to block the Federal Trade Commission's pricing case ...
An earlier FTC report published in July 2024 argued that the six largest PBMs were effectively running a monopoly that gave them enormous power over the price of medicines and allowed them to ...
Below, we summarize the major findings from the Second Report, discuss potential next steps by the FTC (and others), and offer some key takeaways. In the complex world of health insurance ...
The Prescription Drug Affordability Act would aim to stop pharmacy benefit managers, or PBMs, from “exploiting loopholes” to ...
The FTC called out the nation’s leading pharmacy benefit managers for inflating pharmacy costs, affecting both employers and employees.
In the latest executive shakeup at CVS, the pharmacy giant has named a new president of its pharmacy benefit management ...
Outrage against PBMs was on full display when 400 pharmacy professionals in Kansas shuttered their businesses and petitioned ...
For years PBMs have been assailed by pharma companies and Congress, and the new Trump administration looks likely to keep up the barrage.
In this Special Edition of the PBM Policy and Legislative Update, the Mintz Health team partnered with our Antitrust colleagues to analyze the FTC’s Second Report. Please see full publication ...
CVS Health reported $1.6 billion in profit for the fourth quarter, down from a $2 billion haul a year ago, according to its ...
However, a report last year from The House of Representatives and another more recently from the Federal Trade Commission (FTC) argue that PBMs have used this position to drive up drug costs for ...